September 18, 2019

iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage

NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into the initial Statement of Work (“SOW1”) under its Memorandum of Understanding (“MOU”) with AzarGen ...

Continue Reading

August 27, 2019

iBio and CC-Pharming Expand Business Collaboration in China

iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has expanded the scope of its business venture with CC-Pharming Ltd. by granting it an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab (“iBio Rituximab”) product ...

Continue Reading

August 19, 2019

iBio Inks 3D Bioprinting Agreement

iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation (NASDAQ:UTHR), to produce recombinant human collagen ...

Continue Reading

June 19, 2019

iBio Announces First Agreement for Fill-Finish Services

NEW YORK, June 19, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage ...

Continue Reading

June 3, 2019

iBio Launches New Sterile Fill-Finish Services

NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today introduced new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other ...

Continue Reading
1 2